Furthermore, BH3 profiling has demonstrated BCL-2 dependence of myeloblasts, which is in line with preclinical activity of venetoclax in AML [58,59,60,61,62], highlighting it as an attractive therapeutic strategy. Here, BCL2 is linked to acute myeloid leukemia.